Skip to Content

New Additions to Drugs.com for 2019

We update the Drugs.com database on a regular cycle. The following new drug information was added in 2019:

Showing additions for:

Turalio
Aug 19, 2019 - Turalio (pexidartinib) is a kinase inhibitor indicated for the treatment of symptomatic tenosynovial giant cell tumor (TGCT) in adults.

Nubeqa
Aug 5, 2019 - Nubeqa (darolutamide) is an androgen receptor inhibitor (ARi) indicated for the treatment of non-metastatic castration-resistant prostate cancer (nmCRPC).

Baqsimi
Jul 24, 2019 - Baqsimi (glucagon) is a nasally administered antihypoglycemic agent indicated for the treatment of severe hypoglycemia in diabetes patients ages 4 years and older.

Xpovio
Jul 9, 2019 - Xpovio (selinexor) is a nuclear export inhibitor for the treatment of patients adult patients with relapsed or refractory multiple myeloma.

Vyleesi
Jul 8, 2019 - Vyleesi (bremelanotide) is a melanocortin receptor agonist for the treatment of hypoactive sexual desire disorder (HSDD) in premenopausal women.

Slynd
Jun 11, 2019 - Slynd (drospirenone) is a progestin oral contraceptive for birth control.

Piqray
May 30, 2019 - Piqray (alpelisib) is a kinase inhibitor indicated in combination with fulvestrant for the treatment of postmenopausal women, and men, with HR positive, HER2-negative, PIK3CA-mutated breast cancer.

Nayzilam
May 20, 2019 - Nayzilam (midazolam) is a nasally administered benzodiazepine indicated for the acute treatment of seizure clusters.

Qternmet XR
May 7, 2019 - Qternmet XR (dapagliflozin, metformin hydrochloride and saxagliptin) is a sodium-glucose cotransporter 2 (SGLT2) inhibitor, biguanide and dipeptidyl peptidase-4 (DPP-4) inhibitor combination indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.

Skyrizi
Apr 29, 2019 - Skyrizi (risankizumab-rzaa) is an interleukin-23 (IL-23) inhibitor for the treatment of plaque psoriasis.

Balversa
Apr 28, 2019 - Balversa (erdafitinib) is a once-daily, oral, pan-fibroblast growth factor receptor for the treatment of patients with locally advanced or metastatic urothelial cancer.

Duobrii
Apr 27, 2019 - Duobrii (halobetasol propionate and tazarotene) is a corticosteroid and retinoid combination indicated for the topical treatment of plaque psoriasis.

Evenity
Apr 16, 2019 - Evenity (romosozumab) is an anti-sclerostin monoclonal antibody for the treatment of osteoporosis in postmenopausal women at increased risk of fracture.

Dovato
Apr 15, 2019 - Dovato (dolutegravir and lamivudine) is a once-daily, single-tablet, two-drug regimen of the approved drugs dolutegravir (Tivicay) and lamivudine (Epivir) indicated for the treatment of HIV-1 infection in adults with no antiretroviral (ARV) treatment history and with no known resistance to either dolutegravir or lamivudine.

Duaklir Pressair
Apr 15, 2019 - Duaklir Pressair (aclidinium bromide and formoterol fumarate) is a long-acting muscarinic antagonist (LAMA) and long-acting beta2 agonist (LABA) fixed dose combination maintenance bronchodilator for the treatment of COPD.

Mavenclad
Apr 14, 2019 - Mavenclad (cladribine) is a purine antimetabolite indicated for the treatment of relapsing forms of multiple sclerosis (MS).

Mayzent
Apr 1, 2019 - Mayzent (siponimod) is a sphingosine-1-phosphate receptor modulator for the treatment of secondary progressive multiple sclerosis.

Sunosi
Mar 28, 2019 - Sunosi (solriamfetol) is a selective dopamine and norepinephrine reuptake inhibitor (DNRI) for the treatment of excessive sleepiness in adult patients with narcolepsy or obstructive sleep apnea (OSA).

Zulresso
Mar 28, 2019 - Zulresso (brexanolone) is a gamma-aminobutyric acid A (GABAA) receptor positive allosteric modulator indicated for the treatment of postpartum depression (PPD).

Spravato
Mar 6, 2019 - Spravato (esketamine) is a rapid acting, nasal spray formulation of a non-competitive N-methyl D-aspartate (NMDA) receptor antagonist indicated, in conjunction with an oral antidepressant, for use in adults with treatment-resistant depression.

Jeuveau
Feb 13, 2019 - Jeuveau (prabotulinumtoxinA) is a botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines.

Browse additions by year: